95
Participants
Start Date
September 27, 2013
Primary Completion Date
December 22, 2015
Study Completion Date
December 22, 2015
BI 695500
BI695500, once a week for 4 weeks (4 administrations in total)
MabThera
MabThera, once a week for 4 weeks (4 administrations in total)
Auckland Clinical Studies Ltd, Auckland
Semmelweis University, 1st Dept. Internal Medicine, Budapest
AKH - Medical University of Vienna, Vienna
Brussels - UNIV St-Luc, Brussels
The Canberra Hospital, Canberra
UZ Leuven, Leuven
Namur - HOSP Ste-Elisabeth, Namur
Clinical Hospital Centre Zagreb, Zagreb
Hospital Puerta del Mar, Cadiz
"General Hospital of Athens G. Gennimatas", Athens
Haemato-Onkologie Hamburg, Hamburg
Fundación Jiménez Díaz, Madrid
HOP Morvan, Brest
INS Bergonié, Bordeaux
HOP Haut-Lévêque, Pessac
Klinikum Kassel GmbH, Kassel
Hospital Virgen del Rocío, Seville
Gesundheitszentrum Wetterau gGmbH, Bad Nauheim
University Hospital Ostrava, Ostrava-Poruba
Universitätsklinikum Freiburg, Freiburg im Breisgau
Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon
Hôpital la Milétrie - CHU Poitiers, Poitiers
St. Petersburg GUZ City Clinical Oncology Dispensary, Saint Petersburg
BHI of Omsk region - Clinical Oncology Dispensary, Omsk
University Hospital Brno, Brno
Vseobecna fakultni nemocnice V Praze, Prague
Universitätsklinikum Carl Gustav Carus Dresden, Dresden
Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warsaw
Hospital Germans Trias i Pujol, Badalona
Lead Sponsor
Boehringer Ingelheim
INDUSTRY